Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Registration Number
- NCT01472185
- Lead Sponsor
- Gilead Sciences
- Brief Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when given as monotherapy on glycemic control in subjects with type 2 diabetes mellitus (T2DM) who were inadequately controlled with diet and exercise alone and who are treatment naive to antihyperglycemic therapy or have not received antihyperglycemic therapy in the 90 days (or thiazolidinediones \[TZDs\] for at least 24 weeks) prior to screening, and to characterize the relationship between HbA1c reduction and other glycemic parameters in subjects with T2DM.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 465
- Written informed consent
- Males and females, 18 to 75 years old, inclusive
- Documented history of T2DM
- Treatment naïve to antihyperglycemic therapy or having received no prior treatment with antihyperglycemic therapy for at least 90 days (TZDs for at least 24 weeks) prior to screening
- Body mass index (BMI) 25 kg/m2 to 45 kg/m2 inclusive at screening
- HbA1c 7% - 10%, inclusive at screening and at the end of the Qualifying Period (Day 14 +2 days)
- Fasting serum glucose (FSG) of ≥ 130 mg/dL (7.2 mmol/L) and ≤ 240 mg/dL (13.3 mmol/L) at screening and at the end of the Qualifying Period (Day 14 +2 days). A one-time central laboratory re-test of FSG is allowed in subjects with an initial central laboratory FSG ≥ 125 mg/dL (6.9 mmol/L) and < 130 mg/dL (7.2 mmol/L) who are otherwise eligible as determined by the investigator.
- Fasting serum C-peptide ≥ 0.8 ng/mL at screening
- Able and willing to comply with all study procedures during the course of the study
- Females of child-bearing potential must have a negative pregnancy test at screening and must agree to use highly effective contraception methods from screening throughout the duration of the Treatment Period and for 14 days following the last dose of study drug
- At least 80% compliant with dosing during the Qualifying Period
- History of or current diagnosis of type 1 diabetes mellitus
- History of diabetic ketoacidosis, ketosis-prone diabetes, or hyperosmolar hyperglycemic coma
- History of a severe episode of hypoglycemia (≥ 1 episode within 3 months prior to screening or ≥ 2 episodes within 6 months prior to screening), defined as hypoglycemia requiring 3rd party assistance to actively administer carbohydrate, glucagon, or other resuscitative actions due to severe impairment in consciousness or behavior
- Clinically significant complications of diabetes that, in the judgment of the investigator, would make the subject unsuitable to participate in this study
- History of any clinically significant cardiovascular or cerebrovascular event (eg, myocardial infarction [MI], acute coronary syndrome [ACS], recent coronary revascularization [including coronary artery bypass graft procedures or percutaneous coronary intervention], transient ischemic attack or ischemic stroke) ≤ 3 months prior to screening
- Inadequately controlled or unstable hypertension as defined by systolic blood pressure (SBP) > 160 mmHg or diastolic blood pressure (DBP) > 100 mmHg at screening and randomization
- Prolonged QTc interval > 500 msec by ECG at screening, a personal or family history of QTc prolongation, congenital long QT syndrome, or subjects who are receiving drugs that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents, erythromycin, and certain antipsychotics (eg, ziprasidone)
- History of bariatric surgery at any time in the past or any other surgery < 2 months before screening, or planning to undergo surgery during the study. Subjects with a planned minor surgery may be enrolled upon approval by the Medical Monitor.
- Any other hospitalization in the 14 days prior to screening or planned hospitalization at any time during the study
- Significant weight change (± 5%) < 2 months prior to screening or on a weight-loss program and is not in the maintenance phase at screening
- Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease (MDRD) equation < 30 mL/min/1.73 m2 at screening or undergoing any type of dialysis at screening or planning to undergo any type of dialysis during the course of the study.
- History of liver cirrhosis (Child-Pugh Class A, B or C)
- Active liver disease and/or significant abnormal liver function defined as aspartate aminotransferase (AST) > 3x upper limit of the normal range (ULN) and/or alanine aminotransferase (ALT) > 3x ULN and/or serum total bilirubin > 2.0 mg/dL
- History of cancer (except non-melanomic skin cancers or cervical in situ) within 5 years prior to screening
- History of alcohol or other drug abuse < 12 months prior to screening
- Any other clinically significant existing medical or psychiatric condition, including clinically significant laboratory abnormalities, or one requiring further evaluation that, in the opinion of the investigator, could interfere with conduct of the study or interpretation of the data
- Prior treatment with open-label ranolazine or known hypersensitivity or intolerance to ranolazine or any of its excipients
- Treatment with strong or moderate cytochrome (CYP)3A inhibitors or P-glycoprotein (P-gp) inhibitors within 14 days prior to randomization
- Treatment with CYP3A inducers or P-gp inducers within 14 days prior to randomization
- Treatment with CYP3A4 substrates with a narrow therapeutic range (eg, cyclosporine, tacrolimus, sirolimus) within 14 days prior to randomization
- Treatment with simvastatin at a daily dose > 20 mg or lovastatin at a daily dose > 40 mg, within 14 days prior to randomization
- Weight-loss medication or anti-obesity medication (prescription or nonprescription) < 3 months prior to screening
- Treatment with niacin > 200 mg daily; if receiving ≤ 200 mg daily, should be on stable doses for ≥ 90 days prior to screening and for the duration of the study
- Expected or current treatment with systemic corticosteroids (oral or injectable) for > 14 days from screening through the end of the Treatment Period. Topical or inhaled corticosteroid formulations are permitted at any time during the study
- If receiving thyroid replacement therapy, should be on stable doses for at least 6 weeks prior to randomization
- Hemoglobin < 12 g/dL for males; or < 11 g/dL for females, at screening
- Participation in another clinical study involving an investigational drug or device < 30 days prior to screening; participation in another clinical study involving an antihyperglycemic therapy < 90 days prior to screening
- Donation of blood < 2 months prior to screening; plans to donate blood while participating in the study
- Females who are pregnant or breastfeeding
- Other condition(s) that, in the opinion of the investigator, would compromise the safety of the subject, would prevent compliance with the study protocol (including the ability to comply with Mixed Meal Tolerance Test [MMTT]), or would compromise the quality of the clinical study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days. Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks. Participants were required to maintain their diet and exercise regimen. Placebo Exercise Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days. Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks. Participants were required to maintain their diet and exercise regimen. Placebo Diet Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days. Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks. Participants were required to maintain their diet and exercise regimen. Ranolazine Exercise Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days. Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks. Participants were required to maintain their diet and exercise regimen. Ranolazine Ranolazine Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days. Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks. Participants were required to maintain their diet and exercise regimen. Ranolazine Placebo Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days. Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks. Participants were required to maintain their diet and exercise regimen. Ranolazine Diet Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days. Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks. Participants were required to maintain their diet and exercise regimen.
- Primary Outcome Measures
Name Time Method Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 Baseline; Week 24 The average (mean) change from baseline in HbA1c at Week 24 was analyzed.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With HbA1c < 7% at Week 24 Week 24 Change From Baseline in Fasting Serum Glucose at Week 24 Baseline; Week 24 The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed.
Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24 Baseline; Week 24 The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed.
Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at time \[T\] = 120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations and analyzed based on the randomized treatment regardless of actual treatment received.Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24 Baseline; Week 24 The average (mean) change from baseline in incremental change of 2-hour postprandial serum glucose at Week 24 was analyzed.
Trial Locations
- Locations (157)
Thunderbird Internal Medicine/Clinical Research Advantage
🇺🇸Glendale, Arizona, United States
North Central Arkansas Medical Associates
🇺🇸Mountain Home, Arkansas, United States
Desert Sun Clinical Research, LLC
🇺🇸Tucson, Arizona, United States
NZOZ PrimaMED
🇵🇱Kielce, Swietokrzyskie, Poland
NZOZ Specjalistyczna Przychodnia Medyczna Atopia
🇵🇱Krakow, Poland
Vitadiab SRL - Cabinet Medical Dr. Barabas Alina SRL
🇷🇴Brasov, Jud Brasov, Romania
Consultmed SRL
🇷🇴Iasi, Jud. Iasi, Romania
CMI Diabet Nutritie Boli Metabolice Dr. Pop Lavinia
🇷🇴Baia Mare, Jud. Maramures, Romania
CMI Morosanu V. Magdalena
🇷🇴Galati, Judetul Galati, Romania
Spitalul Clinic Judetean de Urgenta "Sf. Apostol Andrei" Galati
🇷🇴Galati, Judetul Galati, Romania
Diabmed Dr. Popescu Alexandrina SRL
🇷🇴Ploiesti, Judetul Prahova, Romania
Tehnomed Trading Srl
🇷🇴Bucharest, Romania
GOU VPO "Chita State Medical Academy" of Minzdravsocrazvitie RF
🇷🇺Chita, Russian Federation
"Clinic of New Medical Technology" Company Limited
🇷🇺Dzerzhinskiy, Russian Federation
The Urals State Medical Academy
🇷🇺Ekaterinburg, Russian Federation
"Krasnoyarsk State Medical University n.a. Prof. V.F. Voyno-Yasenetsky
🇷🇺Krasnoyarsk, Russian Federation
State Healthcare Institution of Moscow "Cardiologival Dispensary #2 of Management Department of South Administrative District"
🇷🇺Moscow, Russian Federation
Federal Centre of Heart, Blood and Endocrinology named after V.A. Almazov
🇷🇺St. Petersburg, Russian Federation
Medical Sanitary Unit of Novo-Yaroslavsky Oil Refinery
🇷🇺Yaroslavl, Russian Federation
Infosphere Clinical Research
🇺🇸West Hills, California, United States
PAB Clinical Research
🇺🇸Brandon, Florida, United States
Suncoast Clinical Research
🇺🇸New Port Richey, Florida, United States
Regenerate Clinical Trials
🇺🇸South Miami, Florida, United States
CTL Research
🇺🇸Eagle, Idaho, United States
MD Medical Research
🇺🇸Oxon Hill, Maryland, United States
LaPorte County Institute for Clinical Research
🇺🇸Michigan City, Indiana, United States
Clinical Trials Management, LLC
🇺🇸Metairie, Louisiana, United States
Clinical Research Solution
🇺🇸New York, New York, United States
Associated Internal Medicine Specialists, P.C.
🇺🇸Battle Creek, Michigan, United States
Albuquerque Clinical Trials
🇺🇸Albuquerque, New Mexico, United States
University of New Mexico Clinical and Translational Science Center
🇺🇸Albuquerque, New Mexico, United States
PharmQuest
🇺🇸Greensboro, North Carolina, United States
PMG Research of Charlotte
🇺🇸Charlotte, North Carolina, United States
Clinical Inquest Center, Ltd.
🇺🇸Beavercreek, Ohio, United States
PMG Research of Salisbury
🇺🇸Salisbury, North Carolina, United States
Blair Medical Associates, Inc, Station Medical Center
🇺🇸Altoona, Pennsylvania, United States
Southeastern Research Associates, Inc.
🇺🇸Taylors, South Carolina, United States
HCCA Clinical Research Solution
🇺🇸Jackson, Tennessee, United States
HCCA Clinical Research Solutions
🇺🇸Smyrrna, Tennessee, United States
New Phase Research & Development
🇺🇸Knoxville, Tennessee, United States
Metabolic Center of Dr. Katarina Raslova Ltd.
🇸🇰Bratislava, Bratislavsky kraj, Slovakia
ENDIAMED s.r.o
🇸🇰Dolny Kubin, Zilinsky kraj, Slovakia
Worthwhile Clinical Trials
🇿🇦Benoni, South Africa
V. P. Komissarenko Institute of Endocrinology and Metabolism of AMS of Ukraine
🇺🇦Kyiv, Ukraine
Vinnytsya Regional Clinical Endocrinology Dispensary
🇺🇦Vinnytsya, Ukraine
Zhytomyr Regional Clinical Hospital
🇺🇦Zhytomyr, Ukraine
Eclipse Clinical Research
🇺🇸Tucson, Arizona, United States
Southland Clinical Research Center, Inc.
🇺🇸Fountain Valley, California, United States
Paul W. Davis, MD, Private Practice
🇺🇸Pine Bluff, Arkansas, United States
Global Research Management
🇺🇸Glendale, California, United States
Spectrum Clinical Research Institute, Inc
🇺🇸Moreno Valley, California, United States
Clearview Medical Research LLC
🇺🇸Santa Clarita, California, United States
A G A Clinical Trials
🇺🇸Hialeah, Florida, United States
Kanizsai Dorottya Hospital
🇭🇺Nagykanizsa, Hungary
NZOZ Centrum Badan Klinicznych
🇵🇱Wroclaw, Dolnoslaskie, Poland
SPZOZ Uniwersytecki Szpital Kliniczny Nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Łodzi, Oddział Kliniczny Diabetologii
🇵🇱Lodz, Lodzkie, Poland
NZOZ Polimedica
🇵🇱Zgierz, Lodzkie, Poland
LANDA - Specjalistyczne Gabinety Lekarskie
🇵🇱Krakow, Malopolskie, Poland
NZOZ Centrum Badan Klinicznych Oswiecim
🇵🇱Oswięcim, Malopolskie, Poland
Manassas Clinical Research Center
🇺🇸Manassas, Virginia, United States
IRC Clinics, Inc
🇺🇸Towson, Maryland, United States
Nemocnice s poliklinikou Havirov
🇨🇿Havirov, Moravskoslezsky kraj, Czech Republic
Humble Cardiology Associates
🇺🇸Humble, Texas, United States
Burke Internal Medicine & Research
🇺🇸Burke, Virginia, United States
Juno Research, LLC
🇺🇸Katy, Texas, United States
Drug Research Center
🇭🇺Balatonfüred, Hungary
Borbanya Praxis Kft., Outpatient Clinic
🇭🇺Nyíregyháza, Hungary
NZOZ Cereo-Med Sp. z o.o.
🇵🇱Lodz, Poland
Miedzyleski Szpital Specjalistyczny w Warszawie
🇵🇱Warszawa, Poland
Spital Clinic Judetean de Urgenta Oradea Stationarul 1
🇷🇴Oradea, Jud Bihor, Romania
Medifarma 98
🇭🇺Nyíregyháza, Hungary
NZOZ Centrum Medyczne Szpital Sw. Rodziny
🇵🇱Lodz, Lodzkie, Poland
Synexus Hungary Ltd
🇭🇺Budapest, Hungary
Markhot Ferenc Hospital
🇭🇺Eger, Hungary
Zala County Hospital
🇭🇺Zalaegerszeg, Hungary
NZOZ Regionalna Poradnia Diabetologiczna
🇵🇱Wroclaw, Dolnoslaskie, Poland
NZOZ Centrum Osteporozy i Chorob Kostno-Stawowych J.Badurski Sp.j.
🇵🇱Bialystok, Poland
Leszek Romanowski Barbara Romanowska "DIABET" Centrum Medyczne s.c.
🇵🇱Chrzanów, Poland
Specjalistyzny Ośrodek Lecznicz-Badawczy
🇵🇱Ostroda, Poland
3rd Central Military Clinical Hospital named after A.A.Vishnevskogo
🇷🇺Arkhangelskoe, Russian Federation
Kemerovo Regional Clinical Hospital
🇷🇺Kemerovo, Russian Federation
City Clinical Hospital # 13 of Avtozavodsky District of Nizhniy Novgorod
🇷🇺Nizhniy Novgorod, Russian Federation
Central Clinical Hospital of Russian Academy of Sciences
🇷🇺Moscow, Russian Federation
Institutul de Diabet, Nutritie si Boli Metabolice "Dr. N. C. Paulescu"
🇷🇴Bucuresti, Romania
O.D. Medica Srl
🇷🇴Bucuresti, Romania
Centru Medical Dr. Negrisanu
🇷🇴Timisoara, jud. Timis, Romania
Novosibirsk State Medical University
🇷🇺Novosibirsk, Russian Federation
Scientific Research Institute of Physiology of Siberian Department RAMS
🇷🇺Novosibirsk, Russian Federation
City Hospital # 38 named after N A Semashko
🇷🇺Pushkin, Russian Federation
Saint-Petersburg City Outpatient Clinic#37
🇷🇺St. Petersburg, Russian Federation
ANO "Medical Centre "XXI century"
🇷🇺St. Petersburg, Russian Federation
Krestovsky Island Medical Institute, LLC
🇷🇺St. Petersburg, Russian Federation
LLC "Reafan"
🇷🇺Novosibirsk, Russian Federation
Rostov State Medical University
🇷🇺Rostov-on-Don, Russian Federation
Ryazan State Medical University
🇷🇺Ryazan, Russian Federation
Medinet, LLC
🇷🇺St. Petersburg, Russian Federation
North-Western State Medical Unversity n.a. I.I.Mechnikov
🇷🇺St. Petersburg, Russian Federation
Military Medical Academy named after S.M. Kirov
🇷🇺St. Petersburg, Russian Federation
Saint-Petersburg state budgetary healthcare institution "City Polyclinic #109"
🇷🇺St. Petersburg, Russian Federation
Clinical Hospital #122 n.a. Sokolov of FMBA
🇷🇺St. Petersburg, Russian Federation
Center "Diabetes", LLC
🇷🇺Samara, Russian Federation
Smolensk State Medical Academy, Sanatorium-Preventorium
🇷🇺Smolensk, Russian Federation
Alexanders City Hospital
🇷🇺St. Petersburg, Russian Federation
St. Elizabeth City Hospital
🇷🇺St. Petersburg, Russian Federation
International Medical Center "SOGAZ", LLC
🇷🇺St. Petersburg, Russian Federation
Saint-Petersburg City Pokrovskaya Hospital
🇷🇺St. Petersburg, Russian Federation
Tyumen State Medical Academy
🇷🇺Tyumen, Russian Federation
Voronezh Regional Clinical Hospital #1
🇷🇺Voronezh, Russian Federation
City Hospital named after N.A.Semashko
🇷🇺Yaroslavl, Russian Federation
Clinical Hospital for Emergency Care named after N.V. Solovyov
🇷🇺Yaroslavl, Russian Federation
Yaroslavl Regional Clinical Hospital
🇷🇺Yaroslavl, Russian Federation
Clinical Center of Kragujevac
🇷🇸Kragujevac, Serbia
METABOLKLINIK s.r.o.
🇸🇰Bratislava, Bratislavsky kraj, Slovakia
Clinical Center of Serbia
🇷🇸Belgrade, Serbia
MEDIVASA s.r.o.
🇸🇰Zilina, Zilinsky kraj, Slovakia
Centre for Diabetes, Asthma and Allergy
🇿🇦Johannesburg, South Africa
Newkwa Medical Centre
🇿🇦Newlands West, Durban, South Africa
Netcare Umhlanga Medical Centre
🇿🇦Kwa Zulu Natal, Umhlanga, Durban, South Africa
Aliwal Shoal Medical & Clinical Trial Centre
🇿🇦Kwa Zulu Natal, South Africa
"Diabetologicka a metabolicka ambulancia Human-care s.r.o"
🇸🇰Kosice, Kosicky kraj, Slovakia
ARETEUS s.r.o., Diabetologicka ambulancia
🇸🇰Trebisov, Kosicky kraj, Slovakia
MediVet s.r.o.
🇸🇰Malacky, Slovakia
Global Clinical Trials
🇿🇦Pretoria, South Africa
Soweto Clinical Trial Centre
🇿🇦Johannesburg, South Africa
City Clinical Hospital#9, Dnipropetrovsk State Medical Academy
🇺🇦Dnipropetrovsk, Ukraine
Educational Scientific Medical Centre "University clinic" of Donetsk National Medical University n.a. M.Gorkiy
🇺🇦Donetsk, Ukraine
State Institution "Institute of Problems of Endocrine Pathology n.a. V.Y. Danylevsky of NAMS of Ukraine"
🇺🇦Kharkiv, Ukraine
Administration of Medical Service and Rehabilitation of "ARTEM" State Holding Company
🇺🇦Kyiv, Ukraine
National Medical University n.a. O.O. Bogomolets, Chair of Family Medicine based on Outpatient Clinic # 2 of Shevchenkovsky District
🇺🇦Kyiv, Ukraine
Municipal Institution Lutsk City Clinical Hospital
🇺🇦Lutsk, Ukraine
Lviv Regional Endocrinology Dispensary
🇺🇦Lviv, Ukraine
Odessa State Medical University
🇺🇦Odesa, Ukraine
Public Institution "City Outpatients' Hospital #20"
🇺🇦Odesa, Ukraine
Helderberg Clinical Trials Centre
🇿🇦Somerset West, South Africa
Tiervlei Trial Centre
🇿🇦Western Cape, South Africa
Moscow City Clinical Hospital #63
🇷🇺Moscow, Russian Federation
National Research Institute
🇺🇸Los Angeles, California, United States
Sacramento Heart and Vascular Medical Associates
🇺🇸Sacramento, California, United States
Boca Raton Clinical Research Associates, Inc
🇺🇸Boca Raton, Florida, United States
Florida Research Network, LLC
🇺🇸Gainesville, Florida, United States
Synergy Therapeutic Partners
🇺🇸Atlanta, Georgia, United States
Central Phoenix Medical Clinic
🇺🇸Phoenix, Arizona, United States
Precision Research Organization
🇺🇸Miami Lakes, Florida, United States
Baptist Diabetes Associates
🇺🇸Miami, Florida, United States
Florida Institute for Clinical Research LLC
🇺🇸Orlando, Florida, United States
Cedar-Crosse Research Center
🇺🇸Chicago, Illinois, United States
Excel Clinical Research, LLC
🇺🇸Houston, Texas, United States
Infinity Research Group, LLC
🇺🇸Oklahoma City, Oklahoma, United States
The University of Texas Southwestern Medical Center at Dallas
🇺🇸Dallas, Texas, United States
Texas Center for Drug Development, PA
🇺🇸Houston, Texas, United States
Cetero Research
🇺🇸San Antonio, Texas, United States
Jean Brown Research
🇺🇸Salt Lake City, Utah, United States
Discovery Clinical Trials
🇺🇸San Antonio, Texas, United States
Highland Clinical Research
🇺🇸Salt Lake City, Utah, United States
Jacksonville Center for Clinical Research
🇺🇸Jacksonville, Florida, United States
NextPhase Clinical Trials, Inc.
🇺🇸Miami Beach, Florida, United States
Medical Sanitary Unit of Minestry of Internal Affairs of Russia in Moscow
🇷🇺Moscow, Russian Federation